Review



dexcom g4 platinum sensor  (Dexcom Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Dexcom Inc dexcom g4 platinum sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Platinum Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4+sensor/dexcom+g4+platinum/med_rxiv__64898__2026__05__13__26353094-140-16-16
    Average 86 stars, based on 1 article reviews
    dexcom g4 platinum sensor - by Bioz Stars, 2026-10
    86/100 stars

    Images

    1) Product Images from "Prevalence, duration, and clinical implications of Continuous Glucose Monitor (CGM) measurement limit capping in type 1 diabetes"

    Article Title: Prevalence, duration, and clinical implications of Continuous Glucose Monitor (CGM) measurement limit capping in type 1 diabetes

    Journal: medRxiv

    doi: 10.64898/2026.05.13.26353094

    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Figure Legend Snippet: Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Techniques Used: Software

    Related Articles

    Clinical Proteomics:

    Article Title: Nocturnal Hypoglycemia in the Era of Continuous Glucose Monitoring.
    Article Snippet: Nocturnal hypoglycemia is a common acute complication of people with diabetes on insulin therapy.. In particular, the inability to control glucose levels during sleep, the impact of external factors such as exercise, or alcohol and the influence of hormones are the main causes.. Nocturnal hypoglycemia has several negative somatic, psychological, and social effects for people with diabetes, which are summarized in this article.

    Article Title: Discrimination and precision of Continuous Glucose Monitoring in staging children with presymptomatic type 1 diabetes.
    Article Snippet: An important distinction from the earlier studies was that we used the Dexcom G6 sensor, which incorporates factory calibration, while the previous studies used Dexcom G4 sensors, which required calibration by the participants (15, 16).

    Article Title: Glucose Management Indicator: Do We Need Device-Specific Equations?
    Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

    Article Title: Continuous Glucose Monitoring in Type 2 Diabetes: A Systematic Review of Barriers and Opportunities for Care Improvement.
    Article Snippet: Maria Assunta Barchiesi a,c , Armando Calabrese a,c , Roberta Costa* a,c , Francesca Di Pillo b,c , Antonio D’Uffizi a,c , Luigi Tiburzi a,c , Erum Zahid a,c a Department of Enterprise Engineering “Mario Lucertini”, University of Rome “Tor Vergata”, Italy *Corresponding author: email: roberta.costa@uniroma2.it; address: Department of Enterprise Engineering “Mario Lucertini”, university of Rome “Tor Vergata”, Via del Politecnico, 1, 00133 Rome, Italy b Department of Computer, Control, and Management Engineering of Sapienza university of Rome, Italy c The authors contributed equally and are listed in alphabetical order © The Author(s) (2025).. Published by Oxford University Press on behalf of International Society for Quality in Health Care.. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.



    Similar Products

    dexcom g4 platinum sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 platinum sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Platinum Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4+sensor/dexcom+g4+platinum/med_rxiv__64898__2026__05__13__26353094-140-16-16
    Average 86 stars, based on 1 article reviews
    dexcom g4 platinum sensor - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    dexcom g4 sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4+sensor/dexcom+g4+sensor/pmc13065641-63-9-9
    Average 86 stars, based on 1 article reviews
    dexcom g4 sensor - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    ed continuous glucose monitors dexcom g4 dexcom g5 dexcom g6 enlite eversence freestyle libre freestyle libre 2 guardian sensor 3 guardian sensor 4  (Dexcom Inc)
    86
    Dexcom Inc ed continuous glucose monitors dexcom g4 dexcom g5 dexcom g6 enlite eversence freestyle libre freestyle libre 2 guardian sensor 3 guardian sensor 4
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Ed Continuous Glucose Monitors Dexcom G4 Dexcom G5 Dexcom G6 Enlite Eversence Freestyle Libre Freestyle Libre 2 Guardian Sensor 3 Guardian Sensor 4, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4+sensor/continuous+glucose+monitors/pm41936552-197-45-49
    Average 86 stars, based on 1 article reviews
    ed continuous glucose monitors dexcom g4 dexcom g5 dexcom g6 enlite eversence freestyle libre freestyle libre 2 guardian sensor 3 guardian sensor 4 - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Journal: medRxiv

    Article Title: Prevalence, duration, and clinical implications of Continuous Glucose Monitor (CGM) measurement limit capping in type 1 diabetes

    doi: 10.64898/2026.05.13.26353094

    Figure Lengend Snippet: Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Article Snippet: Our BGM comparison is restricted to a single arm of a single trial using the older Dexcom G4 Platinum sensor (mean absolute relative difference (MARD) ∼14%), which has lower accuracy than the Dexcom G6 (MARD ∼9%) used in three of our four datasets.

    Techniques: Software